Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.

Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, Darley RL.

Leukemia. 2007 Dec;21(12):2495-505. Epub 2007 Sep 27.

PMID:
17898786
2.

Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.

Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y.

Blood. 1996 Jun 1;87(11):4789-96.

3.

A distinct epigenetic signature at targets of a leukemia protein.

Rossetti S, Hoogeveen AT, Liang P, Stanciu C, van der Spek P, Sacchi N.

BMC Genomics. 2007 Feb 1;8:38.

4.

Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.

Duque-Afonso J, Solari L, Essig A, Berg T, Pahl HL, Lübbert M.

Br J Haematol. 2011 Jun;153(5):612-22. doi: 10.1111/j.1365-2141.2011.08586.x. Epub 2011 Apr 13.

PMID:
21488857
5.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

6.

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG.

Nat Med. 2001 Apr;7(4):444-51.

PMID:
11283671
7.

RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.

Migas AA, Mishkova OA, Ramanouskaya TV, Ilyushonak IM, Aleinikova OV, Grinev VV.

Leuk Res. 2014 Sep;38(9):1102-10. doi: 10.1016/j.leukres.2014.06.002. Epub 2014 Jun 13.

PMID:
24976338
8.

Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.

Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8448-53. Epub 2003 Jun 20.

9.

Acute myeloid leukemia with del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by atypical FISH signals.

Jang JH, Yoo EH, Kim HJ, Kim DH, Jung CW, Kim SH.

Ann Clin Lab Sci. 2010 Winter;40(1):80-4.

PMID:
20124335
10.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

11.
12.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.

Nat Med. 2002 Jul;8(7):743-50. Epub 2002 Jun 24.

PMID:
12091906
13.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

14.

KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.

Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology.

Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28.

PMID:
23053179
15.

Decoding of exon splicing patterns in the human RUNX1-RUNX1T1 fusion gene.

Grinev VV, Migas AA, Kirsanava AD, Mishkova OA, Siomava N, Ramanouskaya TV, Vaitsiankova AV, Ilyushonak IM, Nazarov PV, Vallar L, Aleinikova OV.

Int J Biochem Cell Biol. 2015 Nov;68:48-58. doi: 10.1016/j.biocel.2015.08.017. Epub 2015 Aug 29.

PMID:
26320575
16.

A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.

Fu L, Shi J, Liu A, Zhou L, Jiang M, Fu H, Xu K, Li D, Deng A, Zhang Q, Pang Y, Guo Y, Hu K, Zhou J, Wang Y, Huang W, Jing Y, Dou L, Wang L, Xu K, Ke X, Nervi C, Li Y, Yu L.

Int J Cancer. 2017 Feb 1;140(3):653-661. doi: 10.1002/ijc.30481. Epub 2016 Nov 10.

PMID:
27770540
17.

Leukemia-targeting ligands isolated from phage-display peptide libraries.

Jäger S, Jahnke A, Wilmes T, Adebahr S, Vögtle FN, Delima-Hahn E, Pfeifer D, Berg T, Lübbert M, Trepel M.

Leukemia. 2007 Mar;21(3):411-20. Epub 2007 Jan 25.

PMID:
17252013
18.

Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.

Era T, Asou N, Kunisada T, Yamasaki H, Asou H, Kamada N, Nishikawa S, Yamaguchi K, Takatsuki K.

Genes Chromosomes Cancer. 1995 May;13(1):25-33.

PMID:
7541640
19.

PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).

Zhang Y, Emmanuel N, Kamboj G, Chen J, Shurafa M, Van Dyke DL, Wiktor A, Rowley JD.

Genes Chromosomes Cancer. 2004 Aug;40(4):365-70.

PMID:
15188461
20.

Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.

Engel ME, Hiebert SW.

Cancer Treat Res. 2010;145:127-47. doi: 10.1007/978-0-387-69259-3_8. Review.

PMID:
20306249

Supplemental Content

Support Center